BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 29240024)

  • 21. Preventing and Managing Toxicities of High-Dose Methotrexate.
    Howard SC; McCormick J; Pui CH; Buddington RK; Harvey RD
    Oncologist; 2016 Dec; 21(12):1471-1482. PubMed ID: 27496039
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Methotrexate level discrepancy post-glucarpidase: A pediatric case series and review of literature.
    Kibby D; Trinkman H
    Pediatr Blood Cancer; 2024 Mar; 71(3):e30831. PubMed ID: 38149827
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MTXPK.org: A Clinical Decision Support Tool Evaluating High-Dose Methotrexate Pharmacokinetics to Inform Post-Infusion Care and Use of Glucarpidase.
    Taylor ZL; Mizuno T; Punt NC; Baskaran B; Navarro Sainz A; Shuman W; Felicelli N; Vinks AA; Heldrup J; Ramsey LB
    Clin Pharmacol Ther; 2020 Sep; 108(3):635-643. PubMed ID: 32558929
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reply to: Glucarpidase for the Treatment of Methotrexate-Induced Renal Dysfunction and Delayed Methotrexate Excretion.
    Widemann BC
    Pediatr Blood Cancer; 2016 Feb; 63(2):366. PubMed ID: 26488622
    [No Abstract]   [Full Text] [Related]  

  • 25. Resumption of high-dose methotrexate after acute kidney injury and glucarpidase use in pediatric oncology patients.
    Christensen AM; Pauley JL; Molinelli AR; Panetta JC; Ward DA; Stewart CF; Hoffman JM; Howard SC; Pui CH; Pappo AS; Relling MV; Crews KR
    Cancer; 2012 Sep; 118(17):4321-30. PubMed ID: 22252903
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A second administration of glucarpidase in a different cycle of high-dose methotrexate: Is it safe and effective in adults?
    Domingo-González A; Osorio S; Landete E; Monsalvo S; Díez-Martín JL
    J Oncol Pharm Pract; 2021 Apr; 27(3):734-738. PubMed ID: 32731844
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Commentary.
    Milone MC
    Clin Chem; 2010 Dec; 56(12):1795-6. PubMed ID: 21119036
    [No Abstract]   [Full Text] [Related]  

  • 28. Glucarpidase for the management of elevated methotrexate levels in patients with impaired renal function.
    Fermiano M; Bergsbaken J; Kolesar JM
    Am J Health Syst Pharm; 2014 May; 71(10):793-8. PubMed ID: 24780487
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reduced-dose carboxypeptidase-G2 successfully lowers elevated methotrexate levels in an adult with acute methotrexate-induced renal failure.
    Trifilio S; Ma S; Petrich A
    Clin Adv Hematol Oncol; 2013 May; 11(5):322-3. PubMed ID: 23880719
    [No Abstract]   [Full Text] [Related]  

  • 30. Glucarpidase for the Treatment of Methotrexate-Induced Renal Dysfunction and Delayed Methotrexate Excretion.
    Meyers PA
    Pediatr Blood Cancer; 2016 Feb; 63(2):364. PubMed ID: 26488216
    [No Abstract]   [Full Text] [Related]  

  • 31. Glucarpidase (carboxypeptidase g2) intervention in adult and elderly cancer patients with renal dysfunction and delayed methotrexate elimination after high-dose methotrexate therapy.
    Schwartz S; Borner K; Müller K; Martus P; Fischer L; Korfel A; Auton T; Thiel E
    Oncologist; 2007 Nov; 12(11):1299-308. PubMed ID: 18055849
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reply to: Glucarpidase for the Treatment of Methotrexate-Induced Renal Dysfunction and Delayed Methotrexate Excretion.
    Scott JR; Crews KR
    Pediatr Blood Cancer; 2016 Feb; 63(2):365. PubMed ID: 26488798
    [No Abstract]   [Full Text] [Related]  

  • 33. Early recognition of renal toxicity of high-dose methotrexate therapy: a case report.
    Nowicki TS; Bjornard K; Kudlowitz D; Sandoval C; Jayabose S
    J Pediatr Hematol Oncol; 2008 Dec; 30(12):950-2. PubMed ID: 19131789
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Carboxypeptidase-G2 administration after high-dose methotrexate. Treatment and drug interactions].
    Cózar Olmo JA; Martínez Colmenero C; Peláez Pleguezuelos I; Leiva Gea I; López García AB; de la Cruz Moreno J
    An Pediatr (Barc); 2009 Sep; 71(3):230-4. PubMed ID: 19617010
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Production of "biobetter" variants of glucarpidase with enhanced enzyme activity.
    Al-Qahtani AD; Bashraheel SS; Rashidi FB; O'Connor CD; Romero AR; Domling A; Goda SK
    Biomed Pharmacother; 2019 Apr; 112():108725. PubMed ID: 30970523
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Successful Treatment of Delayed Methotrexate Clearance Using Glucarpidase Dosed on Ideal Body Weight in Obese Patients.
    Krüger C; Engel N; Reinert J; Alsdorf W; Fiedler W; Dierlamm J; Bokemeyer C; Langebrake C
    Pharmacotherapy; 2020 May; 40(5):479-483. PubMed ID: 32239519
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma.
    Widemann BC; Balis FM; Kempf-Bielack B; Bielack S; Pratt CB; Ferrari S; Bacci G; Craft AW; Adamson PC
    Cancer; 2004 May; 100(10):2222-32. PubMed ID: 15139068
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Practical considerations for the administration of glucarpidase in high-dose methotrexate (HDMTX) induced renal dysfunction.
    Widemann BC
    Pediatr Blood Cancer; 2015 Sep; 62(9):1512-3. PubMed ID: 25940351
    [No Abstract]   [Full Text] [Related]  

  • 39. [Carboxypeptidase-G2-rescue in a woman with methotrexate-induced renal failure].
    von Poblozki A; Dempke W; Schmoll HJ
    Med Klin (Munich); 2000 Aug; 95(8):457-60. PubMed ID: 10985069
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effective removal of methotrexate by high-flux hemodialysis.
    Saland JM; Leavey PJ; Bash RO; Hansch E; Arbus GS; Quigley R
    Pediatr Nephrol; 2002 Oct; 17(10):825-9. PubMed ID: 12376811
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.